Background Alterations in nitric oxide (NO) synthesis have been reported in Alzheimer's
disease and vascular dementia. However, as the measurement of NO in biological samples …

L-Arginine/NO pathway is altered in Alzheimer disease (AD). Its clinical relevance and
pathway status in vascular dementia (VaD) are unknown. Using targeted metabolomics (a …

There is good epidemiological evidence that vascular disease predisposes to cognitive
decline and dementia. The impact of vascular disease on dementia is likely to increase …

Background: Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of nitric
oxide (NO) synthase and may alter NO production during pathological conditions …

Background: Urine samples, which capture an individual's metabolic profile, are ideal for the
exploration of non-invasive biomarkers to confirm the amnestic mild cognitive impairment …

Neurodegenerative disorders are one of the greatest global challenges for social and health
care in the twenty-first century. Nowadays, determination of cerebrospinal fluid biomarkers …

Background: This study measured serum concentrations of vascular risk factors, asymmetric
dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in a representative …

Abstract Alzheimer's disease (AD), the most common form of dementia, is characterized by
progressive neurodegeneration and loss of cognitive and memory functions. Although the …

The amino acid L-arginine serves as substrate for the nitric oxide synthase which is crucial
in vascular function and disease. Derivatives of arginine, such as asymmetric (ADMA) and …

L-arginine is a semi-essential amino acid with a number of bioactive metabolites.
Accumulating evidence suggests the implication of altered arginine metabolism in the …